BiotechTube
Mabylon

Mabylon

Zurich, Switzerland· Est.
mabylon.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15.2M

Overview

Mabylon is a private, Zurich-based biotech firm established in 2015, operating in the antibodies and biologics sectors. As a company with limited public information, it is presumed to be in a pre-clinical or early research stage, likely developing a proprietary technology platform for antibody discovery. Its strategic position in the Swiss biotech hub offers access to strong academic and financial networks, but its progress and specific focus areas remain undisclosed to the public.

AntibodiesBiologics

Technology Platform

Proprietary antibody discovery platform (specifics undisclosed)

Funding History

2
Total raised:$15.2M
Series A$12M
Seed$3.2M

Opportunities

The massive and growing global market for therapeutic antibodies presents a significant opportunity for a successful platform.
Operating within the well-funded and innovative Swiss biotech ecosystem provides access to capital, talent, and potential collaboration partners.
A validated platform could lead to lucrative partnerships with large pharmaceutical companies or form the basis of a valuable internal pipeline.

Risk Factors

High technical risk that the undisclosed platform may fail to generate viable drug candidates.
Intense competition from numerous established companies with advanced antibody technologies.
Financial risk associated with running out of capital before achieving a key milestone, given the long and expensive biotech R&D cycle.

Competitive Landscape

Mabylon competes in a crowded field dominated by large biopharma companies (e.g., Roche, Amgen, AbbVie) with extensive internal capabilities and numerous biotechnology companies specializing in antibody discovery (e.g., AbCellera, Adimab, MorphoSys (now part of Novartis)). Success requires demonstrating a clear technological differentiation or advantage in speed, success rate, or ability to target difficult antigens.

More companies in Switzerland →